Nano-X Imaging Ltd. (简称Nanox) 宣布,其创新的Tap2d图像增强技术已获得美国食品药品监督管理局(FDA)的510(K)市场准入许可。此项许可涵盖了该公司旗下的Nanox.ARC以及Nanox.ARC X医学成像系统。
Tap2d技术的引入将显著提升上述系统的图像处理能力,通过先进的算法优化图像质量,为医疗诊断提供更清晰、更精准的影像支持。此次获批标志着Nanox在推进数字医学成像技术商业化进程中迈出了关键一步。
Nano-X Imaging Ltd. (简称Nanox) 宣布,其创新的Tap2d图像增强技术已获得美国食品药品监督管理局(FDA)的510(K)市场准入许可。此项许可涵盖了该公司旗下的Nanox.ARC以及Nanox.ARC X医学成像系统。
Tap2d技术的引入将显著提升上述系统的图像处理能力,通过先进的算法优化图像质量,为医疗诊断提供更清晰、更精准的影像支持。此次获批标志着Nanox在推进数字医学成像技术商业化进程中迈出了关键一步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.